Rubix LS
Rubix LS is a privately held clinical research organization (CRO) providing translational bridging, full-service Phase I/II trial execution, and federal health research, with a differentiated focus on underrepresented patient populations through mobile clinical sites and a 25M+ patient data set.
- Company typePrivate
- Founded2016
- HeadquartersLawrence, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Rubix LS does
Rubix LS (legal name Rubix Life Sciences) is a privately held, for-profit clinical research organization founded in 2016 and headquartered in Lawrence, Massachusetts, with 11–50 employees. The company provides full-service contract research organization (CRO) capabilities spanning pre-clinical studies through Phase II trials (with partnered Phase III/IV support), translational bridging services for early and late-stage evidence planning, and federal health and public health research programs. Its primary customer segments are early-stage biotechnology teams requiring lean proof-of-concept programs, established pharmaceutical sponsors needing Phase I/II execution with complex populations, and federal health agencies requiring public health research and federal contracting expertise.
The company's core technology stack centers on the Patient X Platform — an integrative, interfaceless patient engagement and data-collection solution capturing socioeconomic, behavioral, and cultural data — supported by the TRIDENT boots-on-the-ground workforce, mobile clinical sites, and the Evidence Convergence Platform. Rubix LS claims integration of 25M+ patient records spanning underserved and underrepresented communities, enabling evidence generation that addresses health equity gaps, Complete Response Letters citing inadequate representation, and payer pushback on real-world applicability. AI-driven digital-twin modeling for Project Panacea (a joint venture with TheraSyn Bio developing an investigational topical breast cancer therapy) represents the company's most technically distinctive capability, integrating transdermal absorption, breast-tissue distribution, and tumor-response dynamics in a 100-condition in-silico simulation.
Rubix LS generates revenue through professional services across its three pillars — CRO, translational bridging, and federal health research — under quote-based, scope-dependent pricing that is not publicly disclosed. The go-to-market motion is enterprise field sales targeting pharmaceutical sponsors, biotech companies, and federal agencies, supplemented by content marketing, white papers, and strategic partnership announcements. Recent strategic activity has accelerated meaningfully: the company joined ARPA-H's Investor Catalyst Hub (December 2024), the Equity 2030 Alliance (February 2025), formed the Project Panacea joint venture (2025), and announced a U.S.-Mexico cross-border alliance with Scirena BioVentures (June 2026). The company is led by Founder and CEO Reginald Swift, Ph.D., with Eric Egnet as Chairman and Americo Diaz as Engineering Director. Disclosed funding totals approximately $1.9M across rounds in 2017, 2020, and 2021, and the company has executed two acquisitions (Katalyst Labs in 2018, Clinbotics in 2020).
Rubix LS firmographics
Firmographics- Name
- Rubix LS
- Legal name
- Rubix Life Sciences
- Website
- https://rubixls.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Rubix LS is a privately held clinical research organization (CRO) providing translational bridging, full-service Phase I/II trial execution, and federal health research, with a differentiated focus on underrepresented patient populations through mobile clinical sites and a 25M+ patient data set.
- Ownership category
- akta.pro rank
Rubix LS industry classification
Industry- Product category
- Contract Research Organization (CRO)
- NAICS
- Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (541690)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF)
Keywords
Where Rubix LS is headquartered
LocationHeadquarters
- HQ city
- Lawrence
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Rubix LS business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Contract Research Services (CRO): Full-service CRO capabilities from pre-clinical studies through Phase II, with partnered Phase III/IV support, including protocol development, regulatory strategy, site management, patient recruitment, safety monitoring, data management, and biostatistics
- Translational Bridging Services: Strategic evidence planning and feasibility assessments for early-stage assets, biomarker strategy, endpoint selection, and integrated evidence plans
- Federal Health Research Programs: Partnership with federal agencies on infectious disease surveillance, biodefense programs, and community health initiatives through government contracting
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Rubix LS product offering
Product offeringCore offering
Rubix LS is a clinical research and evidence generation company that designs studies, runs trials, and produces real-world evidence using data from patient populations most underrepresented in research. It delivers full-service CRO capabilities from pre-clinical studies through Phase II, translational bridging and evidence strategy services, and federal health and public health research programs, leveraging 25M+ integrated patient records and mobile clinical infrastructure.
Product overview
Rubix LS operates as a Health Outcomes Architect company providing an integrated suite of clinical research and evidence generation services. The portfolio centers on three pillars: Translational Bridging (early/late translational research and evidence strategy), Contract Research Services (full-service CRO from pre-clinical through Phase II/III), and Federal Health & Public Health Research Programs. Key proprietary platforms include the Patient X Platform for patient engagement and data collection, and the TRIDENT boots-on-the-ground team for community-based recruitment and retention. The Evidence Convergence Platform synthesizes patient-context data with biological, environmental, and healthcare-access signals. Under Project Panacea (joint venture with TheraSyn Bio), the company is developing an investigational topical therapy for early-stage breast cancer using digital-twin modeling. Services are delivered with 25M+ integrated patient records spanning underserved communities, mobile clinical infrastructure, and 90% retention rates in hard-to-reach populations.
Differentiator
Problem solved
Functional benefit
Products and services
- Translational Bridging Early and late translational research services designing decision-grade evidence to support safety, effectiveness, access, and value. Includes feasibility assessments, biomarker strategy, endpoint selection, and integrated evidence plans shaped by data from 25M+ patient records across underserved communities. Targeted at biotech and pharmaceutical sponsors.
- Contract Research Services (CRO) Full-service CRO capabilities from pre-clinical studies through Phase II, with partnered Phase III/IV support. Handles protocol development, regulatory strategy, site management, patient recruitment, safety monitoring, data management, and biostatistics. Targets biotech and pharmaceutical sponsors requiring execution of clinical development programs.
- Federal Health & Public Health Research Programs Partnership with federal agencies on infectious disease surveillance, biodefense programs, and community health initiatives. Applies scientific rigor to national and community-level decision-making with culturally informed engagement strategies and federal contracting experience.
- Patient X Platform An integrative, interfaceless platform designed to simplify patient engagement and optimize data collection for clinical research programs. Captures socioeconomic, behavioral, and cultural data to tailor recruitment and engagement strategies.
- TRIDENT (Boots-on-the-Ground Team) A patient augmentation workforce that supports recruitment, retention, and social engagement in underserved communities. Designed to extend trial access to communities that traditional site networks do not reach.
- Mobile Clinical Sites Mobile clinical infrastructure extending trial access to communities that traditional site networks do not reach. Supports 90% retention rate in hard-to-reach populations through community-embedded research infrastructure.
- Evidence Convergence Platform Infrastructure that maps where breast cancer biology, patient demand, exposure burden, comorbidity burden, and healthcare delivery friction intersect. Combines proprietary patient-context signals with biological, environmental, access, and patient-preference layers.
- Project Panacea A novel topical therapy for early-stage, localized breast cancer (DCIS-first approach) developed in joint venture with TheraSyn Bio. Uses tissue-confirmed pharmacology strategy with digital-twin modeling to evaluate whether localized delivery can reach breast tissue, change expected biology, and limit systemic exposure.
Quantifiable outcome
- 90% trial retention rate in hard-to-reach populations
- +2 more outcomes
Companies that use Rubix LS
Customer profileSegments3 records
Ideal customer profiles3 records
Rubix LS technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability6 records
Feature5 records
Rubix LS partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered major and core.
- Equity 2030 AlliancemajorJoined the Equity 2030 Alliance, a worldwide initiative aimed at fast-tracking gender equity in science, technology, and finance by 2030. Alliance partners include UNFPA, WHO, USAID, UNAIDS, and PATH. Focus areas include improving healthcare delivery, driving data equity, and expanding access to life-saving care.
- ARPA-H Investor Catalyst HubmajorSelected as spoke member of the Investor Catalyst Hub, a regional hub of ARPANET-H nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H). Managed by VentureWell in the Greater Boston area, the hub-and-spoke model aims to accelerate commercialization of groundbreaking and accessible biomedical solutions.
- BioMark Diagnostics Inc.coreStrategic partnership to develop better diagnostic tools for lung cancer screening and improve breast cancer screening programs, especially for women with dense breasts and Triple Negative Breast Cancer (TNBC), focusing on reaching underserved communities. Combines Rubix LS's culturally competent research capabilities with BioMark's liquid biopsy technology platform.
- TheraSyn BiocoreJoint venture for Project Panacea, a novel investigational topical breast cancer therapy. Combines synthetic biology with real-world patient data to develop a non-invasive treatment for early-stage, localized breast cancer. Rubix LS provides AI-driven digital twin modeling and preclinical-to-clinical translation capabilities while TheraSyn Bio contributes the topical gel therapeutic platform.
- Kiffik BiomedicalcoreStrategic partnership to revolutionize early cancer detection through innovative interstitial fluid and aptamer technologies. Rubix LS contributes its culturally competent research capabilities and CLIA/CAP clinical laboratory capacity while Kiffik Biomedical provides aptamer-based diagnostic technology platforms.
- Scirena BioVenturescoreStrategic alliance to accelerate biotech development across the U.S.-Mexico corridor. Partnership announced June 2026, focusing on cross-border biotechnology collaboration and development initiatives.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
Rubix LS competitors and assessment
Company assessmentBroad incumbents
- IQVIA: IQVIA is the world's largest CRO offering full-service clinical development, real-world evidence, and technology-enabled trial design across all phases. Comparable to Rubix LS as the dominant incumbent whose scale and global site network define the competitive landscape Rubix LS must navigate.
- Fortrea: Fortrea (spun out of Labcorp) is a large CRO offering full-service clinical development and clinical trial laboratory services. Comparable as a competitor in CRO services and central lab capability, including CLIA-certified lab operations similar to Rubix LS's CLIA/CAP footprint.
- Parexel International: Parexel is a major private CRO with deep expertise in oncology, rare disease, and complex patient populations, directly aligned with Rubix LS's therapeutic-area focus. Comparable in serving biopharma sponsors needing complex protocol design and global trial execution.
- ICON plc: ICON is a top-3 global CRO delivering full-service clinical research from Phase I through Phase IV across all major therapeutic areas. Direct competitor for the same pharma and biotech sponsor budgets that Rubix LS targets, with substantially greater scale and Phase III/IV capability.
- Syneos Health: Syneos Health is a large CRO offering full-service clinical development and commercial services across all therapeutic areas. Comparable as a competitor for the same biopharma R&D outsourcing budgets.
Direct peers
- Medpace: Medpace is a mid-to-large full-service CRO with strong therapeutic specialization in oncology, rare disease, and infectious disease, very similar to Rubix LS's positioning. Most relevantly comparable as a therapeutically-focused CRO that wins on scientific depth rather than scale alone.
- Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-size, therapeutically-focused CRO with deep expertise in oncology, rare disease, and CNS, sharing Rubix LS's specialty positioning. Comparable as a similarly-sized competitor pursuing complex-population trials with scientific differentiation.
- Veristat: Veristat is a specialty CRO focused on complex clinical programs in oncology and rare disease for small to mid-sized biopharma sponsors. Closely comparable to Rubix LS as a therapeutically-specialized mid-market competitor serving similar biotech sponsor needs.
- CTI Clinical Trial & Consulting Services: CTI Clinical Trial is a specialty CRO with deep expertise in rare disease, hematology, and oncology, comparable in therapeutic focus and mid-market sponsor mix. Similar to Rubix LS in serving complex-population trials for biotech sponsors.
Emerging players
- ObvioHealth: ObvioHealth is a decentralized clinical trial CRO using mobile sites and digital tools to reach patient populations outside traditional site networks. Comparable to Rubix LS's mobile clinical infrastructure and Patient X platform for community-based trial execution.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Rubix LS social profiles
Digital presenceRubix LS compliance and trust
Trust signalCompliance2 records
Rubix LS financial estimates
Financial estimateRevenue estimate
Valuation estimate
Rubix LS leadership team
Management profileNumber of profiles
Profiles3 records
Rubix LS funding detail
Funding detailFunding overview
Funding rounds3 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Rubix LS M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Rubix LS
What does Rubix LS do?
Rubix LS is a clinical research and evidence generation company that designs studies, runs trials, and produces real-world evidence using data from patient populations most underrepresented in research. It delivers full-service CRO capabilities from pre-clinical studies through Phase II, translational bridging and evidence strategy services, and federal health and public health research programs, leveraging 25M+ integrated patient records and mobile clinical infrastructure.
Is Rubix LS a public or private company?
Rubix LS is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Rubix LS founded?
Rubix LS was founded in 2016. It employs 11 to 50 people.
Where is Rubix LS based?
Rubix LS is headquartered in Lawrence, United States, in the North America region.
How does Rubix LS make money?
Three revenue lines are on record. Contract Research Services (CRO) is the primary driver. The others are translational Bridging Services and federal Health Research Programs.
Who are Rubix LS's main competitors?
Broad incumbents on record are IQVIA, Fortrea, Parexel International, ICON plc and Syneos Health. Direct peers are Medpace, Worldwide Clinical Trials, Veristat and CTI Clinical Trial & Consulting Services. ObvioHealth is listed as an emerging player.
Does Rubix LS have an API?
No public API is recorded for Rubix LS.
What industry is Rubix LS in?
Rubix LS's product category is Contract Research Organization (CRO). Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAI, Patient Recruitment, Site Feasibility & Trial Enablement CROs. Its NAICS code is 5417 and its SIC code is 8731.